Firm: Cooper Firms (COO)
Enterprise: The Cooper Firms is a world medical gadget firm. It operates in two enterprise models: CooperVision and CooperSurgical. The CooperVision section is concerned within the contact lens business, whereas the CooperSurgical section is concerned within the fertility and ladies’s well being care market by way of its diversified portfolio of services, together with fertility services, medical gadgets, cryostorage (corresponding to twine blood and twine tissue storage) and contraception. CooperVision’s merchandise embrace MyDay day by day disposable, MyDay day by day disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio consists of INSORB, Lone Star, and the Doppler Blood Stream Monitor. It additionally gives a set of single-use cordless surgical retractors with an built-in multi-light-emitting diode (LED) mild supply and twin smoke evacuation channels, and single-use surgical suction gadgets with an built-in, cordless radial LED mild supply.
Inventory Market Worth: $14.41 billion ($72.49 per share)
Activist: Jana Companions
Possession: n/a
Common Value: n/a
Activist Commentary: Jana is a really skilled activist investor based in 2001 by Barry Rosenstein. They made their identify taking deeply researched activist positions with well-conceived plans for long run worth. Rosenstein known as his activist technique “V cubed.” The three “Vs” have been: (i) Worth: shopping for on the proper worth; (ii) Votes: figuring out whether or not you’ve got the votes earlier than commencing a proxy battle; and (iii) Number of methods to win: having a couple of technique to reinforce worth and exit an funding. Since 2008, they’ve steadily shifted that technique to 1 which we characterize because the three “Ss”: (i) Inventory worth – shopping for on the proper worth; (ii) Strategic activism – sale of firm or spinoff of a enterprise; and (iii) Star advisors/nominees – aligning with high business executives to advise them and take board seats if mandatory.
What’s occurring
On Oct. 20, Jana introduced that they took a place in Cooper Cos. and plan to push for strategic options, together with a possible transaction to mix its contact lens unit with friends corresponding to Bausch + Lomb.
Behind the scenes
Cooper Cos. is a number one international medical gadget firm working by way of two segments: CooperVision and CooperSurgical. CooperVision (66% of income) is targeted on the sale of contact lenses. CooperVision is the worldwide chief by contact wearers and second by way of market share (26%), competing towards Johnson and Johnson (37%), Alcon (26%), and Bausch + Lomb (10%).
The worldwide mushy contact lens market is estimated to be value about $11 billion and is rising at 4% to six% yearly. The section has quite a few tailwinds together with a gentle shift into silicone hydrogel 1-day lenses (about 40% of customers are nonetheless utilizing non-daily lenses), international development involved customers, and excessive obstacles to entry for rivals. As such, it is a nice enterprise that generates EBITDA margins within the mid-30s.
CooperSurgical (33% of income) is targeted on ladies’s well being companies, with 60% of its fiscal yr 2024 income derived from workplace and surgical (Paragard IUDs, stem cell cryostorage, medical gadgets) and 40% from fertility (IVF consumables, tools, genomic and donor companies). Fertility remedy is a $2 billion international market, additionally anticipated to develop at a 4% to six% tempo yearly.
For many of its historical past, Cooper was a pureplay imaginative and prescient enterprise, till they added CooperSurgical within the 90s. Initially, this was a small – arguably tax-motivated – add-on. Nonetheless, the corporate started closely investing on this section in 2017 – spending over $3 billion on the section since.
The issue with this shift is fairly clear – Cooper is successfully siphoning off money from a extremely good contact lens enterprise after which reinvesting it in what most individuals would choose to be a much less engaging enterprise. That is evident within the firm’s declining returns on capital, with CooperSurgical now working at decrease margins than they did in 2017 regardless of these huge investments.
A key issue behind this operational shift could also be administration adjustments. The corporate’s CEO Albert White, who beforehand led CooperSurgical, assumed management shortly after this growth started. This raises a bigger query in regards to the firm’s strategic focus, main many to query why the chief of this firm wouldn’t have experience in its core enterprise.
These strategic missteps have been additional compounded by near-term headwinds throughout each segments, some self-inflicted. For CooperVision, the corporate mismanaged market expectations for the rollout of its new day by day lens product, MyDay Energys, which is now delayed.
For CooperSurgical, its highest high quality enterprise, IVF, has slowed meaningfully, seemingly attributable to feedback from President Donald Trump suggesting potential reimbursements for IVF prices, inflicting sufferers to delay remedy in anticipation of this potential protection. Consequently, top-line natural development fell meaningfully under expectations to 2%, down from 7% the prior quarter, forcing Cooper to considerably decrease its full-year steerage at its third-quarter earnings name, sending the corporate’s share worth down 12.85% the next day. Now, Cooper is buying and selling at a 12-month ahead P/E of 16.4x — a steep low cost to its 10-year common of 23.1x.
All of this has prompted Jana Companions to announce a high portfolio place in Cooper and plans to push for strategic options, together with a possible transaction to mix its contact lens unit with friends corresponding to Bausch + Lomb. Whereas a transaction of this nature would sometimes increase some antitrust issues, this may increasingly really be the alternative case right here.
First, a merger wouldn’t end in a market chief, because the mixed market share of 36% could be just under market chief J&J’s share of 37% and never too far forward of Alcon’s 26% share.
Secondly, these companies are extremely complementary with minimal geographical and product overlap, suggesting a discount within the chance of regulatory hurdles. Notably, Bausch + Lomb has not been shy about their potential curiosity and likewise sees no regulatory points, as CEO Brent Saunders has publicly said {that a} potential mixture with Cooper would “strengthen competitors and create a extra scaled firm within the contact lens section.”
However Bausch + Lomb just isn’t the one potential acquirer. Firms like European eyewear producer EssilorLuxottica might even have curiosity and with even much less regulatory uncertainty.
As for CooperSurgical, there would definitely be personal fairness curiosity, as evidenced by Blackstone and TPG nearing a deal to accumulate peer Hologic. Nonetheless, Cooper shareholders could understand extra worth from the corporate cleansing up this portfolio internally – focusing extra on the higher-multiple IVF enterprise, shedding sure non-core property, and probably placing in new operators to execute a powerful turnaround.
General, with short-term headwinds prone to ease, Cooper has a number of avenues to get better its low cost and open itself up for a possible rerating. Jana’s thesis is easy: these two companies make no sense below the identical roof and a strategic mixture for the imaginative and prescient enterprise might yield $300 million to 500 million synergies, which is quite a bit for a enterprise with $850 million in EBITDA. However the 1st step of their plan is convincing administration that separating the 2 companies is the proper strategic transfer; and regardless of rising public consideration, there isn’t any assure that administration, particularly with one of these working historical past, will agree.
Ought to administration resist, this marketing campaign adjustments dramatically from a strategic thesis to a management/governance thesis, seemingly centered on appointing a brand new CEO with a deep background within the contact lens business to refocus the corporate on its core, whereas nonetheless positioning it for a separation down the road.
Jana just isn’t outwardly calling for a administration change and White could even be the very best individual to guide a standalone CooperSurgical enterprise. However activism is in regards to the energy of the argument and Jana appears to make a persuasive one right here. Let’s hope for all concerned that administration sees it that manner.
Ken Squire is the founder and president of 13D Monitor, an institutional analysis service on shareholder activism, and the founder and portfolio supervisor of the 13D Activist Fund, a mutual fund that invests in a portfolio of activist investments.
